StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.88−0.06 (-3.09%)

Close on Nov 18, 2026Market cap $409.65MP/E –Yield –

CytomX Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

CytomX Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$82.48M. For fiscal 2025 it was -$75.81M. The highest annual figure on record is $168.81M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$75.81M–
FY2024Dec 31, 2024-$86.54M–
FY2023Dec 31, 2023-$56.88M–
FY2022Dec 31, 2022-$112.53M–
FY2021Dec 31, 2021-$120.64M-4189.5%
FY2020Dec 31, 2020$2.95M–
FY2019Dec 31, 2019-$143.98M–
FY2018Dec 31, 2018-$79.31M-147.0%
FY2017Dec 31, 2017$168.81M–
FY2016Dec 31, 2016-$4.21M–
FY2015Dec 31, 2015-$29.01M-196.3%
FY2014Dec 31, 2014$30.14M–
FY2013Dec 31, 2013-$8.74M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.07M–
Q1 FY2026Mar 31, 2026-$25.55M–
Q4 FY2025Dec 31, 2025-$23.44M–
Q3 FY2025Sep 30, 2025-$15.42M–
Q2 FY2025Jun 30, 2025-$15.78M–
Q1 FY2025Mar 31, 2025-$21.16M–
Q4 FY2024Dec 31, 2024-$19.99M–
Q3 FY2024Sep 30, 2024-$20.75M–
Q2 FY2024Jun 30, 2024-$19.65M–
Q1 FY2024Mar 31, 2024-$26.16M-381.3%
Q4 FY2023Dec 31, 2023-$22.23M–
Q3 FY2023Sep 30, 2023-$18.25M–
Q2 FY2023Jun 30, 2023-$25.70M–
Q1 FY2023Mar 31, 2023$9.30M–
Q4 FY2022Dec 31, 2022-$1.58M–
Q3 FY2022Sep 30, 2022-$34.26M–
Q2 FY2022Jun 30, 2022-$34.65M–
Q1 FY2022Mar 31, 2022-$42.05M–
Q4 FY2021Dec 31, 2021-$31.44M–
Q3 FY2021Sep 30, 2021-$29.97M–
Q2 FY2021Jun 30, 2021-$28.31M-129.2%
Q1 FY2021Mar 31, 2021-$30.92M–
Q4 FY2020Dec 31, 2020-$17.87M–
Q3 FY2020Sep 30, 2020-$25.46M–
Q2 FY2020Jun 30, 2020$97.06M–
Q1 FY2020Mar 31, 2020-$50.79M–
Q4 FY2019Dec 31, 2019-$30.18M–
Q3 FY2019Sep 30, 2019-$23.95M–
Q2 FY2019Jun 30, 2019-$48.98M–
Q1 FY2019Mar 31, 2019-$40.86M–
Q4 FY2018Dec 31, 2018-$29.86M-237.2%
Q3 FY2018Sep 30, 2018-$6.60M–
Q2 FY2018Jun 30, 2018-$27.48M-115.9%
Q1 FY2018Mar 31, 2018-$15.36M–
Q4 FY2017Dec 31, 2017$21.77M+1531.8%
Q3 FY2017Sep 30, 2017-$5.80M–
Q2 FY2017Jun 30, 2017$172.87M–
Q1 FY2017Mar 31, 2017-$20.03M–
Q4 FY2016Dec 31, 2016$1.33M–
Q3 FY2016Sep 30, 2016-$15.05M–

More CytomX Therapeutics figures

See a number that looks wrong?